Preclinical reproductive toxicity studies in animals showed fetal death and teratogenicity at doses lower than the recommended human dose. Use of miltefosine during pregnancy is therefore strictly contraindicated, and contraceptive use is mandatory for females of child-bearing age during therapy and for 5 months afterwards. Preclinical studies additionally showed impaired female and male fertility in animals. Stevens-Johnson syndrome has been reported, therefore therapy should be discontinued if an exfoliative or bullous rash occurs during treatment.
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and is only indicated in patients aged 12 years or older. The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Dicoumarol | The therapeutic efficacy of Dicoumarol can be increased when used in combination with Miltefosine. |
| Phenindione | The therapeutic efficacy of Phenindione can be increased when used in combination with Miltefosine. |
| Warfarin | The therapeutic efficacy of Warfarin can be increased when used in combination with Miltefosine. |
| Phenprocoumon | The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Miltefosine. |
| Acenocoumarol | The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Miltefosine. |
| 4-hydroxycoumarin | The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Miltefosine. |
| Coumarin | The therapeutic efficacy of Coumarin can be increased when used in combination with Miltefosine. |
| (R)-warfarin | The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Miltefosine. |
| Ethyl biscoumacetate | The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Miltefosine. |
| Fluindione | The therapeutic efficacy of Fluindione can be increased when used in combination with Miltefosine. |
| Clorindione | The therapeutic efficacy of Clorindione can be increased when used in combination with Miltefosine. |
| Diphenadione | The therapeutic efficacy of Diphenadione can be increased when used in combination with Miltefosine. |
| Tioclomarol | The therapeutic efficacy of Tioclomarol can be increased when used in combination with Miltefosine. |
| (S)-Warfarin | The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Miltefosine. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Miltefosine. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Miltefosine. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Miltefosine. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Miltefosine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Quinisocaine. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Miltefosine is combined with Etrasimod. |